A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
The purpose of this study is to investigate the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin, in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, HF events, or CV death in participants with CKD and HTN.
This study consists of a 4-week dapagliflozin Run-in Period for participants untreated with SGLT2i at screening, and a double-blinded period where participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin.
Site visits will take place at 2-, 4-, 8-, 16-, 34, and 52-weeks following randomisation. Thereafter visits will occur approximately every 4 months.
The study closure procedures will be initiated when the predetermined number of primary endpoint events is predicted to have occurred (N = 845) ie, the PACD. All randomised participants including any participants who have prematurely discontinued study intervention will be scheduled for a SCV within 6 weeks of the PACD. This period can be extended by AstraZeneca.
In case of premature discontinuation of blinded study intervention, participants will continue in the study and receive dapagliflozin 10 mg, unless the participant meets dapagliflozin specific discontinuation criteria. Baxdrostat/placebo should not be administered without dapagliflozin: baxdrostat/placebo should be interrupted if dapagliflozin is interrupted (baxdrostat/placebo may be resumed with dapagliflozin, if dapagliflozin is resumed), and should be permanently discontinued if dapagliflozin is permanently discontinued. If study intervention is temporarily or permanently discontinued, the participant should remain in the study, and it is important that the scheduled study visits (including the PTDV for participants with permanent discontinuation of study intervention) and data collection continue according to the study protocol until the SCV.
Inclusion Criteria:
Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent.
Participants with (a) or (b):
a) eGFR 30-59 mL/min/1.73 m² (local or central laboratory value) AND:
UACR ≥ 30 mg/g (3.39 mg/mmol) and < 500 mg/g (56.5 mg/mmol) (central laboratory value only), or
UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or
UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only).
(b) eGFR 60-75 mL/min/1.73 m² (local or central laboratory value) AND:
UACR ≥ 500 mg/g (56.5 mg/mmol) ) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or
UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only)
[obsolete]
Participants with history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit.
Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit.
Participants with:
Exclusion Criteria:
4. Participants with T1DM will be excluded, except:
For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion.
For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion.
5 Uncontrolled T2DM with HbA1c > 10.5% (> 91 mmol/mol) (central or local laboratory values obtained within 3 months prior to screening or at the Screening Visit).
6 New York Heart Association functional HF class IV at screening.
7 Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation.
8 Documented history of adrenal insufficiency.
9 Any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit.
10 Any acute kidney injury within 3 months prior to the Screening Visit.
11 History of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant).
12 Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months prior to Visit 1).
information.center@astrazeneca.com1-877-240-9479
CABA, C1426, Argentina
CABA, C1426, Argentina
Ciudad Autonoma de Bs As, C1023AAB, Argentina
Ciudad de Buenos Aires, C1019ABS, Argentina
Ciudad de Buenos Aires, C1425AGC, Argentina
Araucania, 4781151, Chile
Huaian, 223399, China
Taian, 271099, China
Copenhagen E, 2100, Denmark
Dakahlia, 35516, Egypt
Dakahlia, 7650030, Egypt
Amagasaki-shi, 660-8550, Japan
Beppu-shi, 874-0011, Japan
Chigasaki-shi, 253-0044, Japan
Fujinomiya-shi, 418-0076, Japan
Hakodate-shi, 041-8680, Japan
Higashihiroshima-shi, 739-0041, Japan
Iizuka-shi, 820-8505, Japan
Inashiki-gun, 300-0395, Japan
Itabashi-ku, 173-0015, Japan
Iwata-shi, 438-8550, Japan
Kamakura-shi, 247-0056, Japan
Kashiwara-shi, 582-0005, Japan
Kasugai-shi, 486-8510, Japan
Kitakyushu-shi, 807-0857, Japan
Kumagaya-shi, 360-0197, Japan
Kurashiki Shi, 701 0192, Japan
Kuse-gun, 613-0034, Japan
Kuwana-shi, 511-0061, Japan
Matsusaka-shi, 515-8557, Japan
Meguro-ku, 153-0051, Japan
Minokamo Shi, 505-8510, Japan
Miyakonojo-shi, 885-0035, Japan
Nagaoka-shi, 940-8621, Japan
Narita-shi, 286-8520, Japan
Obihiro-shi, 080-0848, Japan
Shibuya-ku, 151-8528, Japan
Tanabe-shi, 646-8558, Japan
Toyoake-shi, 470-1192, Japan
Yaizu-shi, 425-8505, Japan
Yoshida-gun, 910-1193, Japan
D.F, 14000, Mexico
Manadaluyong City, 1552, Philippines
Al-Ahsa, 36428, Saudi Arabia
Riyadh/MENA, 11426, Saudi Arabia
Newton, 2113, South Africa
Cheonan-si, 31151, South Korea
Palma deMallorca, 07010, Spain
Yung Kang City, 71044, Taiwan
Banphaeo, 74120, Thailand
Mueang, 50200, Thailand
Phutthamonthon, 73170, Thailand
Ubonratchathani, 34000, Thailand
Haliliye, 63040, Turkey (Türkiye)
Chernivtsі, 58002, Ukraine